PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) pl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Oncol
Hauptverfasser: Patel, Jyoti D., Socinski, Mark A., Garon, Edward B., Reynolds, Craig H., Spigel, David R., Olsen, Mark R., Hermann, Robert C., Jotte, Robert M., Beck, Thaddeus, Richards, Donald A., Guba, Susan C., Liu, Jingyi, Frimodt-Moller, Bente, John, William J., Obasaju, Coleman K., Pennella, Eduardo J., Bonomi, Philip, Govindan, Ramaswamy
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society of Clinical Oncology 2013
Schlagworte:
ORIGINAL REPORTS
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881367/
https://ncbi.nlm.nih.gov/pubmed/24145346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.9626
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge